InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,022.21
(
0.00%
)
US TECH 100
17,069.60
(
0.21%
)
Dow Jones
37,753.31
(
0.00%
)
Brent Oil
86.86
(
-0.14%
)
Bitcoin
62,457.08
(
1.92%
)
Post# of 251501
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

NY1972

Send PM Follow Ignore
Followers 4
Posts 1191
Boards Moderated 0
Alias Born 10/03/2015

NY1972

Re: dewophile post# 210827

Sunday, 04/23/2017 11:10:46 PM

Sunday, April 23, 2017 11:10:46 PM

Post# of 251501
Enrolling MRD+ patients in relapsed AML, CLL, MM.... must be the top priority for CMO now. Additional CMR will validate TTI621's role in IO.

J&J also has JNJ-63709178, a potent humanized CD123 x CD3 in P1 AML. They were looking for a IgG1 CD47 mAb that provides a therapeutic window with limited toxicity.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up